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May 14, 2013:2021–6(49%), device alarms (28%), and hurting one’s partner (21%) were
cited as barriers. Driveline site, awkwardness, obstruction, heart
rate, and energy drain were cited infrequently, although 72% of
respondents reported the equipment was “somewhat” of an obsta-
cle or a “major” obstacle to satisfaction. A total of 47% of patients
felt their LVAD negatively affected self-image, which more than
half felt was at least somewhat important for sexual satisfaction.
Responses to open-ended questions were highly variable (Table 1).
Although LVADs improve cardiac output, the impact on endo-
thelial function, psychological health, social circumstances, and rela-
tionships may not be uniformly favorable. A significant proportion of
respondents reported no change or worsening of sexual function,
although it is unclear if this was driven by physiological changes or a
myriad of other factors that impact sexual health. In contrast to
findings from a prior study (2), we were surprised that only a minority
f participants reported improvement, particularly in desire, after an
VAD. The lack of change does not follow the improvement in the
uality of life that is expected after implantation.
To the best of our knowledge, this study provides the largest
xamination of sexual function in female LVAD recipients. Sexual
ysfunction was more prominent in females, who were more likely to
ate the impact of body image highly, mirroring findings in healthy
eople. Changes in factors more related to blood flow alterations, such
s arousal and orgasm, decreased similarly between sexes.
The study design and low response rate limit the ability to draw
rm conclusions from our data. These data should inform subse-
uent studies designed to evaluate and improve understanding of
he specific factors involved in sexual health post-LVAD. The data
o provide us, however, with important insights on how we may
mprove patient care. Equipment was frequently cited as an
bstacle; and along with the fear of damaging the LVAD, it
ppears that improvements to external components may have a
avorable impact on sexual function.
Willingness to address concerns about sexual function may foster
iscussion regarding the safety of and barriers to sexual activity.
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Representative Responses to Open-Ended QuestionsTable 1 Representative Responses to Open-Ended Questions
Advice to other patients about sexual function and the LVAD?
a) “It does not necessarily increase sexual function or pleasure.”
b) “You still can have a sex life, however it will likely change.”
c) “Don’t let VAD get in your way. It was put there to make you feel better
and be able to do more and this is one of these things.”
Advice physicians should give patients about sexual function and the
LVAD?
a) “None unless asked.”
b) “Never to give up. It gets better with time.”
c) “Physicians should open the subject of sex. Patients need to be
reassured that it is OK. They should offer help, if possible, for
impotence.”
d) “LVAD is used to improve quality of life. Do what you feel comfortable
with doing but also be careful.”
Anything else about how your LVAD has impacted the role of sex in your
life that you would like to share?
a) “Probably the least improved part of life before to after VAD.”
b) “Worried about partner’s weight on my stomach if we move wrong.”
c) “I am leery about sex because I am afraid of hurting my site or harming
the controller. I am afraid of pulling accidentally on the leads.”itaramesh Emani, MDue Duval, PHD¶
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Letters to the Editor
B-Type Natriuretic
Peptide Assay for Complex
Congenital Heart Diseases
Clinical Relevance
Versus Methodological Issues
We read with interest the paper by Eindhoven et al. (1), under-
scoring the clinical usefulness of B-type natriuretic peptide (NP)
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May 14, 2013:2021–6assay (either of brain NP [BNP] or of the N-terminal fragment of
BNP [NT-proBNP]) in complex congenital defects (congenital
heart disease [CHD]). Their literature review is mostly focused on
the applications of NPs for the follow-up of some CHD (1).
However, we would like to remind that NPs may be also used for
neonatal screening purposes (2,3), differential diagnosis, prognos-
tic stratification (in children undergoing cardiac surgery) (2,4), and
to guide the surgical/medical management of CHD, including
complex defects (2), as it is the case for the setting of heart
failure (5).
Moreover, variability associated with both physiological and
methodological sources is a relevant issue to be taken into account
for proper clinical use of NPs in patients of pediatric age.
In particular, NP levels in healthy subjects are very high during
the first 4 days of life, while decreasing thereafter, rapidly through-
out the first week, with a further slow progressive reduction for up
to the first month of life (6). After the first month of life, NPs
show no more significant age- or gender-related differences up to
puberty (2,6).
Furthermore, the measured NP concentrations, as well as
reference ranges and decisional cutoff values, are strictly method
dependent (5). The diagnostic accuracy of NPs in neonates with
CHD, too, varies up to the first month of life, with low levels in
the first 3 days after birth (2). These findings are likely due to the
different timecourse of NP levels observed either in healthy
neonates or in newborns with CHD. In the first 3 days of life,
BNP levels are very high in both healthy subjects and patients,
whereas after the fourth day peptide levels rapidly and progres-
sively fall only in healthy neonates. For these reasons, we have
suggested two different cutoff values to rule in or out CHD: the
first, characterized by higher values from 1 to 3 days of life; and the
second with lower values from days 4 to 30 of life (2). Further-
more, because various methods have been employed by different
authors (1,2), the influence of the analytical contribution to
BNP/NT-proBNP concentration variability, by the assay method,
needs to be evaluated (2).
In conclusion, the assay of NPs may be considered as helpful for
screening, diagnostic, prognostic, and follow-up purposes, to be
included into an integrated approach to children with suspected or
ascertained complex CHD. Nevertheless, biological (age-related)
and method-related variability needs to be taken into account
when interpreting NP values in this setting, especially in the
neonatal age.
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Reply
We thank Dr. Cantinotti and colleagues for their interest in our
article (1) and for their valuable addition. We fully agree with
Cantinotti et al. that brain natriuretic peptides (NPs) are of
potential use for other purposes as differential diagnosis and to
guide medical and surgical management of congenital heart disease
(CHD). In our systematic review we aimed to provide a clear
overview of average NP levels for the 3 most commonly encoun-
tered complex congenital heart defects and the relation with
cardiac function to determine its possible use in the cardiologists’
daily practice. The use of this biomarker at young pediatric age is
so far mainly studied in mixed cohorts of various forms of CHD
(2). As we looked at disease-specific NP values, these studies were
not included in our review article. Nevertheless, daily changes in
BNP in the first days of life and suggested cutoff values for NPs in
this period clearly provide valuable diagnostic information for both
neonatologists and pediatric cardiologists.
Cantinotti et al. also note that the various assay methods used to
determine NP levels measure different NP concentrations and have
assay method–specific cutoff values (3).We acknowledge this fact, and
it was our main reason to withhold us from a direct comparison of the
observed NP values by performing a formal meta-analysis. By report-
ing both NP values for CHD patients and, when reported, NP values
for healthy controls per study (Figure 2 [1]), we aimed to demonstrate
the observed differences objectively without drawing any overall
conclusions. Despite known differences between assay kits, the mea-
sured NP levels and observed correlations were comparable, strength-
ening the potential clinical use of NPs in CHD (1). Furthermore, the
dditional prognostic value of the marker remains to be clarified by
arger longitudinal studies.
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